To this end, we present a de terministic in silico tumor model which will accur

Go down

 To this end, we present a de terministic in silico tumor model which will accur Empty To this end, we present a de terministic in silico tumor model which will accur

Post  huwan123456 on Mon Jun 01, 2015 5:13 am

Of the 80 in silico predictions, 61 predictions showed agreement with in vitro experimental effects. Examination of drug sensitivity correlation for all eight GBM patient derived cell lines, for the many 13 medication is summarized in Additional file 1 Table S7. Figures 5A H and 6A H show a drug wise comparison of in silico predictions and in vitro experimental [You must be registered and logged in to see this link.] success created with testing one uM concentration of each drug on these cell lines. Result of tyrosine kinase inhibitors on patient derived GBM cells To the EGFR family members inhibitor lapatinib, simulation stud ies predicted SK429, SK748 and SK1035 to be resistant, which had been confirmed by in vitro information. Similarly, model ing predicted GBM8, SK102, SK262 and SK987 to be delicate and these predictions were in agreement with experimental information.

On the other hand, modeling predicted GBM4 to become resistant to lapatinib although in vitro information showed GBM4 to become extremely sensitive to lapatinib. For that tyrosine kinase inhibitor nilotinib, the model predicted GBM8 for being delicate though every one of the other profiles to get resistant. In vitro stud ies demonstrated that GBM8 was without a doubt delicate [You must be registered and logged in to see this link.] to nilotinib as predicted, but there was a mismatch using the experimental success for two lines SK262 and SK1035. Experimentally, SK262 was observed to be sensi tive, whereas SK1035 was within the borderline of sensitiv ity and resistance. For imatinib, simulation predicted that all GBM lines except GBM8 had been resist ant. The experimental outcomes corroborated with this particular in silico prediction.

Sunitinib was the other multi tyrosine kinase inhibitor examined. Our simulation predicted GBM8, SK102 and SK987 for being sensitive to sunitinib; however, only GBM8 was found for being sensitive in vitro. SK262 was predicted to become re sistant to sunitinib but in vitro information observed it to get moder ately sensitive. [You must be registered and logged in to see this link.] However, GBM4, SK429, SK748 and SK1035 were uncovered to get resistant in both simulation and experimental data. Impact of other medicines on patient derived GBM cells In addition to the tyrosine kinase inhibitors, correlation be tween in silico predictions and experimental results for that 8 patient derived GBM cell lines was also tested for drugs which include pitavastatin, everolimus, celecoxib and bortezomib.

For bortezomib, all profiles had been predicted for being delicate and these predictions matched with in vitro ex perimental outcomes. For everolimus, in vitro final results have been in agreement with simulation pre dictions for all lines except SK429. Our in silico model predicted GBM4, SK262, SK429, SK748 and SK1035 to get resistant to celecoxib; these pre dictions matched with in vitro outcomes. Having said that, GBM8, SK102 and SK987 have been predicted to show reasonable sensi tivity to celecoxib, but have been identified for being resistant in vitro. For pitavastatin, the simulation pre dicted 5 patient derived GBM cell lines to be sensitive, of which SK987 was located to be resistant in vitro. Then again, of your cell lines predicted to be resistant, SK1035 was sensitive in vitro and didn't match together with the prediction. These information demonstrate a 76. 25% agreement amongst in silico predictions of drug response and in vitro experi psychological information in patient derived GBM cell lines.


Posts : 229
Join date : 2014-03-14

View user profile

Back to top Go down

Back to top

- Similar topics

Permissions in this forum:
You cannot reply to topics in this forum